Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Oncolytic Virus Therapy Market?

The market for oncolytic virus therapy has been experiencing rapid growth over the last few years. The market is estimated to increase from $0.19 billion in 2024 to $0.23 billion in 2025, boasting a compound annual growth rate (CAGR) of 25.0%. A variety of factors have contributed to this historic growth, including enhanced genetic engineering methods, a greater comprehension of the tumor microenvironment, triumphs in clinical trials and regulatory approvals, the emergence of immunotherapy in cancer management, and progress in gene delivery systems.

In the forthcoming years, the market size for oncolytic virus therapy is predicted to undergo significant expansion, eventually reaching $0.55 billion in 2029, with an impressive compound annual growth rate (CAGR) of 23.7%. Several factors drive this expansion in the predicted timeframe, including the development of oncolytic virus platforms, combined treatments with immune checkpoint inhibitors, the evolution of personalized medicine, and the enlarging scope of clinical trials, all underpinned by regulatory support and guidelines. Significant trends for this forecast period encompass progress in delivery system technology, advancements in synthetic biology, strategic collaborations and partnerships within the biopharmaceutical sector, progress in both virology and immunology, and a focus on paediatric oncology.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Industry Forces Are Driving The Oncolytic Virus Therapy Market Forward?

The escalating number of cancer instances is projected to fuel the expansion of the oncolytic virus therapy market in the future. Cancer refers to a collective of illnesses marked by the unregulated proliferation and dissemination of aberrant cells in the body. Oncolytic virus therapy presents a potential solution to selectively target and eradicate cancer cells while also eliciting an immune response against the tumor. This provokes a dual action mechanism for efficient cancer treatment. For instance, the American Cancer Society Inc., a non-profit organization based in the US, predicted in January 2023 that there will be 609,820 cancer-related deaths and 1,958,310 newly identified cancer instances in the US in 2022. Consequently, the continual rise in cancer instances is propelling the oncolytic virus therapy market’s growth.

How Is The Oncolytic Virus Therapy Market Organized By Different Segments?

The oncolytic virus therapymarket covered in this report is segmented –

1) By Therapy Type: HSV-Based Oncolytic Virus Therapy; Adenovirus-Based Oncolytic Virus Therapy; Reovirus; Poxviruses; NDV (Newcastle Disease Virus); Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses; Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer; Lung Cancer; Prostate Cancer; Melanoma; Brain Tumor; Blood Cancer

4) By End-User: Hospitals; Specialty Clinics; Cancer Research Institutes

Subsegments:

1) By HSV-Based Oncolytic Virus Therapy: Talimogene Laherparepvec (T-VEC); Other HSV-Based Therapies

2) By Adenovirus-Based Oncolytic Virus Therapy: Onyx-015; AdV-5/3-D24; Other Adenovirus-Based Therapies

3) By Reovirus: Reolysin; Other Reovirus Therapies

4) By Poxviruses: JX-594 (OncoVac); Other Poxvirus Therapies

5) By NDV (Newcastle Disease Virus): NDV-Based Therapies; Other NDV Applications

6) By Other Therapy Types: Combination Therapies; Other Emerging Oncolytic Virus Therapies

What Current And Upcoming Trends Are Shaping The Oncolytic Virus Therapy Market?

Prominent businesses in the oncolytic virus therapy market are focusing on securing regulatory approvals to accelerate the launch of novel cancer treatments. This process of regulatory approval involves the assessment and sanctioning of medical goods, including medications, biologics, and medical tools, by healthcare authorities for distribution in the market. For instance, in March 2024, the FDA granted Fast Track designation to ImmVira, a biotechnology firm based in China, for their oncolytic virus treatment, MVR-T3011 IT. This therapy is designed to manage recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in subjects who have observed disease progression after platinum-based chemotherapy and at least one previous anti-PD-1/PD-L1 therapy. This Fast Track designation is designed to hasten the development and review process for treatments targeting serious illnesses with unmet healthcare needs.

Who Are The Primary Market Leaders In The Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market include Pfizer Inc., Johnson & Johnson, Sorrento Therapeutics Inc., AbbVie Inc., AstraZeneca plc, Amgen Inc., Boehringer Ingelheim Group, Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Kissei Pharmaceutical Co. Ltd., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Adze Biotechnology, Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Circio Holding ASA, Lokon Pharma AB, Provectus Biopharmaceuticals Inc., Vibalogics

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

How Do Regional Dynamics Influence The Oncolytic Virus Therapy Market Performance?

North America was the largest region in the oncolytic virus therapy market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

Browse Through More Reports Similar to the Global Oncolytic Virus Therapy Market 2025, By The Business Research Company

Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Anti Cancer Mabs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

Solid Tumor Cancer Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model